Immuneering Corp (NASDAQ:IMRX) currently has a daily average trading volume of 5.66M but it saw 4070760 shares traded in last market. With a market cap of 71.75M USD, the company’s current market price of $2.42 came rising about 6.14 while comparing to the previous closing price of $2.28. In past 52 weeks, the stock remained buoying in the range of price level as high as $9.00 and as low as $1.00. In the recent trading on the day, stock has struck highest price mark of $2.275 while lowest mark touched by it was $2.64.
Taking a look at 20-day trading activity of Immuneering Corp (IMRX) gives us an average price of $1.50, while its current price level is -73.11% below from 52-week high level whereas it is 142.00% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.31 while that of 200 days or SMA-200 reads an average of $3.31. A closer look into the stock’s movement over the week reveals that its volatility is standing at 42.32% during that period while stretching the period over a month that decreases to 16.43%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 69.15 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Needham which reiterated the stock as “Buy” in its note to investors issued on March 15, 2024, recommending a price target of between $20 and $15 for it. Jefferies issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $16 and $3.
Over the week, IMRX’s stock price is moving 69.23% up while it is 126.17% when we observe its performance for the past one month. Year-to-date it is -67.07% down and over the past year, the stock is showing a downside performance of -69.41%.
The company is expected to be releasing its next quarterly report in October, for which analysts forecasted an EPS of -0.55 while estimate for next year EPS is -1.89. In next quarter, company is expected to be making quarterly sales of $nan as analysts are expecting the sales for current fiscal year at $nan and seeing the company making $nan in sales next year. Moreover, analysts are in estimates of $nan for current-quarter revenue.
Currently, Immuneering Corp’s total number of outstanding shares is 29.27M. Company’s return on investment (ROI) stands at -79.75% and return on equity (ROE) at -61.81%. Stock’s beta reads -0.76. Stock has a price to book (P/B) ratio of 1.08. Its return on asset (ROA) is -55.52% on average.
